{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:22:08Z","timestamp":1792678928343,"version":"4.5.0"},"reference-count":81,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2017,5,4]]},"DOI":"10.1080\/14787210.2017.1309292","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T11:50:49Z","timestamp":1490097049000},"page":"467-481","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection"],"prefix":"10.1080","volume":"15","author":[{"given":"Ay\u015fe Elif","family":"\u00d6zdener","sequence":"first","affiliation":[{"name":"School of Pharmacy and Health Sciences, Fairleigh Dickinson University, Florham Park, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Eun","family":"Park","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy, New York, NY, USA"},{"name":"Department of Pharmacy, State University of New York (SUNY) Downstate Medical Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kalabalik","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Health Sciences, Fairleigh Dickinson University, Florham Park, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Gupta","sequence":"additional","affiliation":[{"name":"Infectious Disease Care, Randolph, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"CIT0001","unstructured":"HIV in the United States: at a glance. Oct 2016. http:\/\/www.cdc.gov\/hiv\/statistics\/overview\/ataglance.html."},{"key":"CIT0002","unstructured":"US Public Health Services. Preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2014: a clinical practice guidelines. May 2014. http:\/\/www.cdc.gov\/hiv\/pdf\/prepguidelines2014.pdf."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0020027"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302816"},{"key":"CIT0012","unstructured":"Delaney KP, Sanchez T, Bowles K, et al. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. Feb 2016. http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2016\/889.pdf."},{"key":"CIT0013","unstructured":"Bush S, Magnuson D, Rawlings M, et al. Racial characteristics of FTC\/TDF for pre-exposure prophylaxis users in the US. June 2016. http:\/\/www.abstractsonline.com\/pp8\/#!\/4060\/presentation\/16214."},{"key":"CIT0014","unstructured":"Truvada [package insert]. Gilead Sciences, Inc. http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/truvada\/truvada_pi.pdf."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6786"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"CIT0017","unstructured":"Mannheimer S, Hirsch-Moverman Y, Loquere A, et al. Feasibility of intermittent PrEP among US MSM: data from the Harlem site. July 2015. http:\/\/www.natap.org\/2015\/IAS\/IAS_85.htm."},{"key":"CIT0018","unstructured":"Holtz TH, Chitwarakorn A, Curlin ME, et al. A comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok. July 2015. http:\/\/www.natap.org\/2015\/IAS\/IAS_99.htm."},{"key":"CIT0019","unstructured":"Bekker L-G, Hughes J, Amico R, et al. HPTN 067\/ADAPT: background and methods and Cape Town results. July 2015. http:\/\/www.natap.org\/2015\/IAS\/IAS_98.htm."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193748"},{"key":"CIT0021","unstructured":"Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women [abstract 26LB]. Feb 2015. http:\/\/www.croiconference.org\/sessions\/facts-001-phase-iii-trial-pericoital-tenofovir-1-gel-hiv-prevention-women."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311355110"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157061"},{"key":"CIT0024","volume-title":"ClinicalTrials.gov [Internet]","author":"Albert Einstein College of Medicine, Inc","year":"2000"},{"key":"CIT0025","volume-title":"ClinicalTrials.gov [Internet]. Bethseda (MD): national Library of Medicine (US)","author":"Auritec pharmaceuticals","year":"2000"},{"key":"CIT0026","unstructured":"FDA News Release. FDA approves new treatment for HIV. Nov 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm471300.htm."},{"key":"CIT0027","unstructured":"Highleyman L Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation. Feb 2015. http:\/\/www.aidsmap.com\/Tenofovir-alafenamide-equally-effective-but-safer-for-kidneys-and-bones-than-current-formulation\/page\/2949354\/. Accessed Jan 3, 2017."},{"key":"CIT0028","unstructured":"Massud I, Mitchell J, Babusis D. et al. Chemoprophylaxis with oral FTC\/TAF protects macaques from rectal SHIV infection. Abstract presented at Conference on Retroviruses and Opportunistic Infections (CROI). Feb 22-25, 2016; abstract number 107."},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1904-6"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-15"},{"key":"CIT0031","unstructured":"Tivicay [package insert]. GlaxoSmithKline. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Tivicay\/pdf\/TIVICAY-PI-PIL.PDF#page=1."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000168"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03909-14"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-192"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000301"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248707"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010298"},{"key":"CIT0038","unstructured":"Frank I, Grant R, Mayer K. et al. ECLAIR: phase 2A safety and PK study of cabotegravir LA in HIV-uninfected men. Boston, MA: 2016."},{"key":"CIT0039","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). Safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC), for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men. 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720094?term=cabotegravir&rank=6."},{"key":"CIT0040","unstructured":"National Institute of Allergy and Infectious Diseases. NIH launches first large trial of a long-acting injectable drug for HIV prevention: study to test efficacy, safety or injectable cabotegravir compared to daily oral PrEP. Dec 2016. https:\/\/www.niaid.nih.gov\/news-events\/nih-launches-first-large-trial-long-acting-injectable-drug-hiv-prevention. Accessed on Mar 5, 2017."},{"key":"CIT0041","unstructured":"Selzentry [package insert]. ViiV Healthcare. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Selzentry\/pdf\/SELZENTRY-PI-MG-IFU.PDF."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1086\/655661"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020209"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ae69c5"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01204-13"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001108"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000769"},{"key":"CIT0048","volume-title":"Abstract presented at Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Gulick R","year":"2016"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02871-14"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.14.79"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001043"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1738-7"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000702"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602046"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.05.003"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.07.051"},{"key":"CIT0058","unstructured":"International Partnership for Microbicides, Inc. PK and safety study of vaginal rings containing dapivirine and levonorgestrel (DAP)\/LNG. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02855346. Accessed on Mar 5, 2017."},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005075"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.118"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30113-8"},{"key":"CIT0062","volume-title":"ClinicalTrials.gov [Internet]","author":"PATH","year":"2016"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000164"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw042"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.08.004"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02201-15"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00082-16"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000216"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw578"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e00f5"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2634"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115511"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000798"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.4.20013"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000217"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108742"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000987"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0355-4"},{"key":"CIT0080","unstructured":"Highleyman L. PrEP use exceeds 79,000 in US pharmacy survey, but some groups lagging behind. July 2016. http:\/\/www.aidsmap.com\/PrEP-use-exceeds-79000-in-US-pharmacy-survey-but-some-groups-lagging-behind\/page\/3072084\/. Accessed Dec 21, 2016."},{"key":"CIT0081","unstructured":"Garner W, Wilson B, Hirsch A, et al. Preexposure prophylaxis for HIV prevention: the use and effectiveness of PrEP in the Veterans Health Administration (VHA). Oct 2016. https:\/\/idsa.confex.com\/idsa\/2016\/webprogram\/Paper60122.html."}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2017.1309292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T21:21:52Z","timestamp":1599427312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2017.1309292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5,4]]}},"alternative-id":["10.1080\/14787210.2017.1309292"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2017.1309292","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}